Serina Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug $(IND)$ application for SER-252, an investigational therapy for advanced Parkinson's disease. The clearance allows the company to proceed with regulatory and site-level activities to support the initiation of a planned Phase 1b registrational clinical study. The FDA has provided feedback supporting the proposed clinical trial design under a 505(b)(2) New Drug Application (NDA) pathway. Phase 1b clinical site start-up and regulatory activities in Australia are also underway as part of the global registrational program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000005), on January 28, 2026, and is solely responsible for the information contained therein.